tbuckley/cabot-search huggingface dataset:
OP0046 Risk factors for adverse pregnancy outcome in antiphospholipid antibodies carriers: results from a multicenter italian cohort over 20 years of experience
Authors: MG Lazzaroni, L Andreoli, CB Chighizola, T Del Ross, M Gerosa, A Kuzenko, M-G Raimondo, A Lojacono, F Ramazzotto, S Zatti, L Trespidi, PL Meroni, V Pengo, A Ruffatti, A Tincani
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). In particular, for aPL carriers (patients with aPL positivity with no thrombotic or obstetric history) pregnancy outcome and treatment are still undefined. <h3>Objectives</h3> To review pregnancy outcome in a large multicenter cohort of aPL carriers patients, according to different serological profile and treatment protocols. <h3>Methods</h3> We reviewed 69 pregnancies in 61 patients, prospectively followed in 3 Italian centers (1994–2015). Patients with any complication in previous pregnancies or concomitant autoimmune diseases were excluded. aPL profile was defined as the combination of the 3 criteria tests for aPL (Lupus Anticoagulant, anti-cardiolipin, anti-Beta2 Glycoprotein I). APO was defined as: miscarriage (&lt;10w), fetal death (≥10w), severe preterm delivery (≤34w) with or without preeclampsia (PE), HELLP syndrome or perinatal death. <h3>Results</h3> Regarding aPL profile: 44 (64%) were single positive, 16 (23%) were double and 9 (13%) were triple. aPL non-criteria manifestations were present in 6 (9%) and lupus-like manifestations in 5 (7%). Eight pregnancies had a combination treatment with prophylactic low molecular weight heparin (LMWH) plus low dose aspirin (LDA), 37 had LDA alone and 24 had no treatment. We observed 2 thrombotic events (3%, 1 deep venous thrombosis and 1 ischemic stroke) and 6 APO (9%): 3 fetal deaths and 3 pre-term birth ≤34w with PE. We compared 8 complicated (6 APO,2 thrombosis) with 61 non-complicated pregnancies (Table 1). Acquired risk factors (p:0.006), non-criteria aPL (p:0.018) and lupus-like manifestation (p:0.010), triple positive aPL profile (p:0.001) were associated with APO. The combination treatment was also more frequent in APO pregnancies (p:0.005). <h3>Conclusions</h3> Acquired risk factors,aPL profile (triple positivity), lupus-like and non-criteria aPL manifestations could represent risk factors for pregnancy complications and could determine failure to conventional treatment.These patients may deserve additional treatment, for example LMWH at higher/anti-coagulant dose or immunomodulatory treatment (e.g.hydroxychloroquine, also considering its anti-platelet/anti-thrombotic effects). <h3>Disclosure of Interest</h3> None declared
Volume load‐induced right ventricular dysfunction in animal models: insights in a translational gap in congenital heart disease
Authors: Guido P.L. Bossers, Quint A.J. Hagdorn, Mark Jan Ploegstra, Marinus A.J. Borgdorff, Herman H.W. Silljé, Rolf M.F. Berger, Beatrijs Bartelds
Journal: European Journal of Heart Failure (2017)
FRI0390 European multicentre study validates elf test as biomarker of fibrosis in systemic sclerosis
Authors: G Abignano, J Blagojevic, L-A Bissell, RB Dumitru, S Eng, Y Allanore, J Avouac, S Bosello, C Denton, O Distler, G Ferraccioli, S Jordan, M Matucci-Cerinic, V Ong, M Messenger, M Hutchinson, MH Buch, P Emery, F Del Galdo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The Enhanced Liver Fibrosis (ELF) test is a serum test including the serum concentrations of amino-terminal pro-peptide of procollagen type III (PIIINP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and hyaluronic acid (HA). A recent single centre study showed that ELF score and its components are markers of overall fibrosis in systemic sclerosis (SSc) mainly reflecting skin and lung involvement (1). <h3>Objectives</h3> To determine the value of ELF score and its single analytes in an independent multicentre cohort of SSc patients. <h3>Methods</h3> 254 SSc patients from 6 European Rheumatology Centres were included in this study. Clinical data were collected at time of sampling. Serum samples were collected and stored according to EUSTAR biobanking recommendations (2). Sera were analysed employing a high-throughput in vitro diagnostic (Siemens Alpha-Centaur). Statistical analysis was performed with SPSS software V.24. <h3>Results</h3> The 254 SSc patients had a mean age 55.8±13.8 years, and included 209 females and 80 patients with diffuse cutaneous SSc (dcSSc). ELF score was overall higher in males than in females (p=0.0236) as well as in dcSSc compared to limited cutaneous SSc patients (p=0.0015). ELF score and the single markers significantly correlated with the degree of skin involvement (mRSS) and inversely correlated with FVC%, TLC% and DLCO%. Concordantly all markers significantly correlated with skin and lung severity as assessed by the Medsger9s scale (Table 1). TIMP-1 and PIIINP levels were higher in patients with lung fibrosis assessed by chest HRCT scan (p=0.0126 and p=0.0308 respectively). Significant correlation (p&lt;0.0001) was found between ELF score, TIMP-1, PIIINP, HA and total disease severity and activity. Multivariate analysis indicated that age (p&lt;0.0001), mRSS (p&lt;0.0001) and DLCO% (p=0.005) were independently associated with ELF score. <h3>Conclusions</h3> The value of ELF score as independent marker of skin and lung involvement is confirmed in a second independent multicentre cohort of SSc patients. A longitudinal study paired with analysis of large cohort of healthy controls is currently on going to identify a SSc specific test with the highest predictive value for skin and lung progression independently of age and gender. <h3>References</h3> Abignano G et al. Ann Rheum Dis. 2014. Beyer C et al. Ann Rheum Dis. 2011. <h3>Disclosure of Interest</h3> None declared
メシチリン耐性黄色ブドウ球菌(MRSA)の管理のための熱的に誘発されるバクテリオファージのエンドリシンCHAPKとバクテリオファージのリソスタフィンの放出
Authors: Hathaway Hollie, Ajuebor Jude, Stephens Liam, Coffey Aidan, Potter Ursula, Sutton J. Mark, A A Jenkins Toby
Journal: Journal of Controlled Release (2017)
Do we need to reconsider best practice in goal setting for physical activity promotion?
Authors: Christian Swann, Simon Rosenbaum
Journal: British Journal of Sports Medicine (2017)

Goal setting is one of the most widely applied and universally accepted strategies used to increase physical activity (PA). Goals are defined as internal representations of desired outcomes, events or processes,1 such as losing 10 kg (outcome), completing a marathon (event) or being more active (process). Goal setting is particularly relevant for individual-level interventions, for example, when set by practitioners/clinicians prescribing exercise or making referrals. Indeed, the current trend of self-monitoring using wearables (Fitbit-like devices) is essentially rooted in achieving PA change through goal setting. Given recent calls for a ‘ movement for movement ’2 in response to a burgeoning evidence base regarding the importance of PA prescription and counselling,3 ensuring that the right goals are established, for the right person, and at the right time has clear implications for the effectiveness of interventions targeting both clinical and non-clinical populations. Furthermore, given that the greatest potential public health impact of PA promotion lies in assisting physically inactive individuals engage in some PA, as opposed to increasing the volume of PA among those …
Financial conflicts of interest among editorialists in high-impact journals
Authors: V Kaestner, V Prasad
Journal: Blood Cancer Journal (2017)

Prior studies have shown that financial relationships between editorialists and the biopharmaceutical industry are associated with increased likelihood of favorable descriptions of evidence, even when that evidence is unfavorable. 1How financial conflicts among editorialists should be managed-whether disclosure or recusal is necessary-has been a longstanding debate in medicine.In 1990 under editor and chief Arnold Relman, the New England Journal of Medicine (NEJM) introduced a policy of recusal for editorialists with financial ties to drugs or devices discussed in the editorial. 2This policy was re-affirmed in 1993 by editors Jerome Kassirer and Marcia Angell, 3 but in 2002, citing difficulty in recruiting authors, Jeffrey Drazen and Gregory Curfman relaxed this requirement, and instituted the current policy where editorialists 'not have any significant financial interest in any biomedical company relevant to the topics and products discussed in the article 4 ', where significant became defined as $10 000 or less in financial conflicts. 5Other journals, such as the Journal of the American Medical Association (JAMA) and Annals of Internal Medicine maintain a disclosure policy for relevant conflicts of interest for editorial writers.Using the public disclosure of financial payments from manufactures of medical drugs or devices to physicians, we sought to identify the prevalence and amount of financial conflicts of interest among editorial writers at high impact factor journals and drug and devices discussed in the editorial.We first chose the three highest impact factor journals in general medicine based in the United States, and as ranked by the Thompson Reuter impact factor (http://www.scimagojr.com/journalrank.php).
Mechanistic insight into the function of the microbiome in lung diseases
Authors: Niki D.J. Ubags, Benjamin J. Marsland
Journal: European Respiratory Journal (2017)

The lung harbours a diverse array of microbes whose dynamic composition is influenced by both host and environmental factors. Thus far, most studies have described the microbial composition of healthy or diseased lungs and provided an overview of the differences between topographical locations within the respiratory tract. However, insight into the functional mechanisms underlying host−microbe interactions and how they might drive lung health and disease are limited. This review provides an overview of the current mechanistic understanding of the microbiome, crosstalk between tissue compartments, and its involvement in respiratory diseases.
Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin’s glucose-lowering effects
Authors: Cheol Hwangbo, Jingxia Wu, Irinna Papangeli, Takaomi Adachi, Bikram Sharma, Saejeong Park, Lina Zhao, Hyekyung Ju, Gwang-woong Go, Guoliang Cui, Mohammed Inayathullah, Judith K. Job, Jayakumar Rajadas, Stephanie L. Kwei, Ming O. Li, Alan R. Morrison, Thomas Quertermous, Arya Mani, Kristy Red-Horse, Hyung J. Chun
Journal: Science Translational Medicine (2017)

Inhibition of FABP4 rescues defective apelin signaling, decreases fatty acid accumulation, and promotes insulin sensitivity.
FRI0006 Protein citrullinations by pad enzymes promote dendritic cell transdifferentiation into osteoclast and generate targets for ra-specific antibodies
Authors: B Réthi, A Krishnamurthy, J Ytterberg, M Sun, V Joshua, H Wähämaa, N Tarasova, J Steen, V Malmström, AI Catrina
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Immature dendritic cells (DCs) are able to trans-differentiate into osteoclasts (OCs) although the mechanisms regulating this process are little understood. We have recently described an important role for protein citrulliantion and peptidylarginine deiminase (PAD) enzyme activity in the regulation of OC development (1). <h3>Objectives</h3> We studied the molecular bases of DC-OC trans-differentiation and aimed at understanding the role of protein citrullination in this process. <h3>Methods</h3> Monocyte-derived DCs and peripheral blood CD1c+ DCs were cultured in the presence of osteoclastogenic cytokines. Polyclonal ACPAs were isolated from the serum of RA patients and applied in OC cultures. DC and OC differentiation was analyzed <i>in vitro</i> using gene expression analyses, flow cytometry-based methods, DC-T cell co-culture experiments, tartrate-resistant acid phosphatase stainings and osteolysis assays. Protein citrullination was monitored with the help of mass spectrometry. PAD activity was measured by ELISA. <h3>Results</h3> Different DC types showed different capacities to develop into OCs. OC-prone DCs were characterized by little immunogenicity and their development was potentiated by the increase of lactic acid, a side product of glycolytic metabolism. The more immunogenic DC types, characterized by prominent ability to migrate towards secondary lymphoid tissues and trigger T cell activation, showed a limited capacity to develop into OCs (2). The differentiation switch towards the OC lineage was associated with increased activity of the Protein Arginine Deiminase (PAD) enzymes and with higher level of protein citrullination in DCs. The PAD inhibitor Cl-Amidine efficiently interfered with OC development form DC precursors. In addition, the deposition of citrullinated proteins on the cell surface made the cells sensitive for anti-citrullinated protein autoantibodies, which could further stimulate DC-OC trans-differentiation through inducing the cytokine IL-8. <h3>Conclusions</h3> Our results indicated that DCs are heterogenic in their ability to form OCs and lineages for immunostimulatory and OC-prone DCs might separate early during DC differentiation. Plasticity towards OC differentiation might be influenced by the metabolic environment and the upregulation of PAD activity in DCs. <h3>References</h3> Krishnamurthy A et al. Ann Rheum Dis 2016. Nasi A et al. J Immunol 2013. <h3>Disclosure of Interest</h3> None declared
FRI0736-HPR Validity and reliability of performance tests assessing balance and fall risk in patients with total knee arthroplasty
Authors: DC Sarac, B Unver, S Cekmece, V Karatosun
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Total knee arthroplasty (TKA) is a common surgical intervention that is performed with an aim to treat severe osteoarthritis (OA) of knee. Even though there is a rapid improvement in knee pain, functional improvement is limited in the following year after the surgery. Increased fall risk due to impairments in balance is one of the most common limitations after TKA. Therefore, balance and fall risk evaluation is an essential part of the assessment. <h3>Objectives</h3> The aim of this study was to determine the validity and reliability of various performance tests that are used for evaluating balance and fall risk in patients with TKA. <h3>Methods</h3> This study included 32 OA patients (27 F, 5 M) who undergone TKA surgery 6 months prior to the study. Mean age and BMI of the patients were 64±10,58 and 30,49±5,87, respectively. Participants performed the Timed Up and Go Test (TUG), 10 Meter Walk Test (10MWT), Single Leg Stance Test (SLST), Functional Reach Test (FRT), 2 Minute Walk Test (2MWT), Five Times Sit to Stand Test (5x SST) as performance tests. Each of the tests was performed twice, with a 1-day interval. ICC models were used to determine the test-retest reliability. Berg Balace Scale (BBS) was used as the reference standard to establish concurrent validity. <h3>Results</h3> All tests showed good to excellent reliability (ICC &gt;0.94) except SLST which showed moderate to good reliability (ICC=0.74). Three of the tests (SLST, 10 MWT, 5x SST) found to have good to excellent validity (r&gt;0.75) and three (2 MWT, TUG, FRT) found to have moderate to good reliability (r&gt;0.69). Results are presented in details at Table 1 and Table 2. <h3>Conclusions</h3> TUG, 10MWT, SLST, FRT, 5x SST and 2 MWT are reliable and valid outcome measures, and could be used to assess balance and fall risk in patients with TKA. MDC scores presented in this study can be used to evaluate change in performance over time or effectiveness of interventions. 2 MWT and 5x SST were determined as the most reliable and valid methods among the investigated tests. <h3>Disclosure of Interest</h3> None declared
THU0617 Information on disease and treatment of patients with rheumatic diseases treated with subcutaneous biologicals: sources and satisfaction. rheu-life survey
Authors: F de Toro, E Batlle, C González, M Calvo, M Arteaga, L Cea-Calvo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To know the sources by which patients with rheumatic diseases treated with subcutaneous (SC) biological drugs obtain information on their treatment, their satisfaction with the information received from the hospital staff and their perception of the degree of information they have. <h3>Methods</h3> RHEU-LIFE was a survey handed by 50 rheumatologists from Spanish outpatients hospital offices to patients on SC biological drugs. They completed the survey anonymously at home and returned it by pre-paid post-mail. They selected from a list their sources of information (being able to mark all their sources), their satisfaction with the information received from the hospital staff and whether they had sought additional information in other sources. <h3>Results</h3> The survey was handed to 1000 patients and 592 returned it (59.2%, mean age 51.7 years, 57.6% women). The source of information most frequently mentioned was the rheumatologist (table) and, infrequently, the nurse or the hospital pharmacist. 46.1% had received information on the SC biological only orally, 6.0% written and 45.2% in both ways. The percentages quite or very satisfied with the information received were 42.6% and 44.5% respectively, 10.6% felt "neither satisfied nor dissatisfied" and 2.1% and 0.2% dissatisfied or very dissatisfied. The % quite/very satisfied was higher when the information came from the rheumatologist (89.6% vs 59.6% when the rheumatologist was not mentioned as source of information, p&lt;0.001), and also when information was given both oral and written (92.8% vs 86.1% if only oral information was given, p=0.0125). Some 45.2% had sought information on the SC biological in sources different to the hospital staff, the % being higher among younger patients (&lt;43 years: 65.2%: 43–52 years: 51.4%, 53–61 years: 39.1%, &gt;61 years: 20.6%, p&lt;0.001) those with higher education level (without studies: 14.3%, primary: 31.6%, secondary: 55.6%, vocational: 59.5%, university or higher degrees: 64.9%, p&lt;0.001), and in those treated with a first biological SC drug (49.9%, vs. 37.7% and 37.2% with a second or third or further, p=0.014). <h3>Conclusions</h3> Patients with rheumatic diseases mention the rheumatologist as their main source of information. The % who mentioned nurses or pharmacists was low, although the latter are very frequently visited for dispensing the drug. Satisfaction with the information received was high, but clearly lower when the rheumatologist did not inform the patient. Nearly half reported having sought information in sources other than the hospital staff. <h3>Acknowledgements</h3> Endorsed by ConArtritis (National Coordinator of Patients with Arthritis). Funded by Merck Sharp &amp; Dohme of Spain <h3>Disclosure of Interest</h3> None declared
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons
Authors: Asa Radix, Andrew M. Davis
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes
Authors: James J. Chamberlain, Rita Rastogi Kalyani, Sandra Leal, Andrew S. Rhinehart, Jay H. Shubrook, Neil Skolnik, William H. Herman
Journal: Annals of Internal Medicine (2017)

The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence. The committee rated the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards of Care were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.
SP0042 The art of juggling - a patient's perspective
Authors: FM Catrina
Journal: Annals of the Rheumatic Diseases (2017)

Diagnosed with ankylosing spondylitis since 2006, when just turned 24 years old. I was very demoralized and could not understand why I have rheumatic pains bigger than my grandmother 70 years old. I did not understand why I can not go, just do anything wrong to anyone. Slowly, slowly I began to understand the disease and help doctors started to move again.But my secret to healthy aging, was family. Therefore we understand that positive thinking can help me more than any drug, and how you can have a more positive attitude as if in a nice family environment? <h3>Disclosure of Interest</h3> None declared
Peak hyperammonemia and atypical acute liver failure: The eruption of an urea cycle disorder during hyperemesis gravidarum
Authors: Nicolas Weiss, Fanny Mochel, Marika Rudler, Sophie Demeret, Pascal Lebray, Filomena Conti, Damien Galanaud, Chris Ottolenghi, Jean-Paul Bonnefont, Marc Dommergues, Jacques Bernuau, Dominique Thabut
Journal: Journal of Hepatology (2017)